Last updated on February 2018

Home Therapy With VPRIV in Gaucher's Disease


Brief description of study

The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Gaucher's Disease receiving their enzyme replacement therapy with VPRIV (Velaglucerase alfa)at their home setting compared to receiving the infusions at the clinic or at doctor's practice.

Clinical Study Identifier: NCT01356537

Contact Investigators or Research Sites near you

Start Over

Yildiz Yildiz, MD

Landeskrankenhaus Bregenz
Bregenz, Austria
  Connect »

Florian B. Lagler, MD

Paracelsus Medizinische Privatuniversit t Salzburg
Salzburg, Austria
  Connect »

Vassiliki Konstantopoulou, MD

AKH, Allgemeines Krankenhaus der Stadt Wien
Wien, Austria
  Connect »

Thomas Stulnig, MD

Medical University of Vienna
Wien, Austria
  Connect »

Thomas Stulnig, MD

Medizinische Universit t Wien
Wien, Austria
  Connect »

Shire Contact

Endocrinology in the center
Erlangen, Germany
  Connect »

Shire Contact

Facharzt f r Chirurgie und Orthop die
Hamburg, Germany
  Connect »

Shire Contact

Gastroenterological FOCUS PRACTICE Dr. med. Hans Werner Karch
Kirn, Germany
  Connect »

Eugen Mengel, MD

Universit tsklinikum Mainz
Mainz, Germany
  Connect »

Arndt Rolfs, MD

Albrecht-Kossel-Institut f r Neuroregeneration (AKos)
Rostock, Germany
  Connect »

Peter Clemens, MD

Helios Klinikum Schwerin
Schwerin, Germany
  Connect »

Prof. Michael Leichsenring, MD

Universit tsklinikum Ulm
Ulm, Germany
  Connect »

Shire Contact

Praxis f r Innere Medizin
Wallgau, Germany
  Connect »

Achim Rothe, MD

Gemeinschaftspraxis f r H matologie und Onkologie
Köln, Germany
  Connect »

Shire Contact

Group Practice, Drs Klaus Michels and Michels Alexander
Mühlhausen, Germany
  Connect »

Claudia Regenbogen, MD

Klinikum rechts der Isar
München, Germany
  Connect »